

# Acasti Pharma Inc

09:41 26 Nov 2019

## Acasti Pharma leaps closer to TRILOGY 1 results after it wraps up patient visits

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) is one step closer to revealing results from its critical TRILOGY 1 trial of lead drug CaPre, which treats severe hypertriglyceridemia.

The pharmaceutical company told shareholders on Tuesday that the last patient in the study completed their final visit, clearing the way to reporting results by the end of the year.

Laval, Quebec-based Acasti also said it expects the last patient to complete their final visit in the TRILOGY 2 study in early January 2020, with topline results expected towards the end of January 2020.

### READ: Research firm Encode Ideas starts coverage on biotech Acasti Pharma

Acasti is conducting clinical trials on its prescription drug candidate CaPre, a highly purified omega-3 phospholipid concentrate stemming from krill oil to treat hypertriglyceridemia, or elevated levels of fat in the blood, that can lead to increased risk of cardiovascular disease and pancreatitis.

Past studies have shown CaPre to achieve statistically significant reduction of triglycerides and non-HDL cholesterol levels in patients with various levels of hypertriglyceridemia. CaPre also demonstrated potential to reduce cholesterol that is bad for the body and increase the type of cholesterol that the body needs.

Topline results from TRILOGY 1 will include a readout of the primary endpoint, which is intended to show CaPre's overall impact on lowering triglycerides after 12 weeks compared to placebo. Safety and tolerability, such as overall adverse events will also be reported.

### TRILOGY studies nearing completion

Pierre Lemieux, Acasti's CEO, told investors that the company is nearing completion of TRILOGY 2 with approximately 85% of randomized patients having completed the study.

Data clean-up is now 97% and 75% completed for TRILOGY 1 and TRILOGY 2, respectively, according to Lemieux.

"Assuming these results are positive, we intend to present the full data set at important scientific meetings in the first half of 2020 and file an NDA by mid-2020 to obtain regulatory approval for CaPre in the United States," Lemieux informed investors in a statement.


The important secondary and exploratory endpoint results are expected to be completed before the end of March 2020 and will include additional triglyceride secondary endpoints.

Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

**Price:** 0.53

**Market Cap:** \$47.81 m

### 1 Year Share Price Graph



April 2019 September 2019 March 2020

### Share Information

**Code:** ACST

**Listing:** TSX-V

<b>52 week</b>	<b>High</b>	<b>Low</b>
	4.05	0.35

**Sector:** Pharma & Biotech

**Website:** [www.acastipharma.com](http://www.acastipharma.com)

### Company Synopsis:

*Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).